Lodelcizumab
Lodelcizumab is a monoclonal antibody targeting PCSK9. Lodelcizumab can be used for the research of hypercholesterolemia[1].
Product Specifications
CAS Number
[1355338-54-3]
UNSPSC
12352203
Target
PCSK9
Type
Inhibitory Antibodies
Related Pathways
Metabolic Enzyme/Protease
Field of Research
Others
Assay Protocol
https://www.medchemexpress.com/lodelcizumab.html
Purity
99.89
Solubility
10 mM in DMSO
Smiles
[Lodelcizumab]
Molecular Weight
(145.6 kDa)
References & Citations
[1]Pordy, et al. Anti-PCSK9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis. Patent. WO2017031151 A1.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6183265-01 0.1 mL
DTYMK (deoxythymidylate Kinase (thymidylate Kinase), CDC8, FLJ44192, TMPK, TYMK) (HRP)
Ask
View Details 
MBS6183265-02 5x 0.1 mL
DTYMK (deoxythymidylate Kinase (thymidylate Kinase), CDC8, FLJ44192, TMPK, TYMK) (HRP)
Ask
View Details MBS1097230-01 0.05 mg (E-Coli)
Recombinant Rhodobacter sphaeroides Lipoyl synthase (lipA)
Ask
View Details MBS1097230-02 0.05 mg (Yeast)
Recombinant Rhodobacter sphaeroides Lipoyl synthase (lipA)
Ask
View Details 
MBS1097230-03 0.2 mg (E-Coli)
Recombinant Rhodobacter sphaeroides Lipoyl synthase (lipA)
Ask
View Details